In sum, these results strongly support our hypothesis that concomitant CDK4/6 inhibition effectively prevents the unwanted HSR that contributes to therapeutic failure when treating CRC cells with HSP90 inhibitors. Here, CDK4 is linked to colorectal carcinoma.